Adaptin Bio Financials
This page shows Adaptin Bio (APTN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Adaptin Bio's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Adaptin Bio has elevated debt relative to equity (D/E of 619158.00), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Adaptin Bio's current ratio of 0.29 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Adaptin Bio generates a -100000000.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Adaptin Bio passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Adaptin Bio generates $0.92 in operating cash flow (-$4.8M OCF vs -$5.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Adaptin Bio earns $-74.5 in operating income for every $1 of interest expense (-$5.4M vs $73K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Adaptin Bio reported -$5.2M in net income in fiscal year 2025. This represents a decrease of 3106.5% from the prior year.
Adaptin Bio earned $-0.66 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1962.5% from the prior year.
Cash & Balance Sheet
Adaptin Bio held $459K in cash against $0 in long-term debt as of fiscal year 2025.
Adaptin Bio had 9M shares outstanding in fiscal year 2025. This represents an increase of 170.3% from the prior year.
Margins & Returns
Adaptin Bio's ROE was -100000000.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Adaptin Bio invested $1.8M in research and development in fiscal year 2025.
APTN Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $779K+128.8% | $340K+447.8% | $62K | N/A | $683K-0.4% | $685K+244.3% | $199K | N/A |
| SG&A Expenses | $897K-24.0% | $1.2M+49.8% | $788K | N/A | $312K+279.4% | $82K-18.3% | $101K | N/A |
| Operating Income | -$1.7M-10.2% | -$1.5M-78.8% | -$850K | N/A | -$995K-29.6% | -$767K-156.0% | -$300K | N/A |
| Interest Expense | N/A | N/A | $73K | N/A | $107K+117.3% | $49K+24.0% | $40K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.7M-10.2% | -$1.5M-152.2% | -$603K | N/A | -$1.1M-35.3% | -$819K-141.2% | -$339K | N/A |
| EPS (Diluted) | $-0.20-11.1% | $-0.18-80.0% | $-0.10 | N/A | $-0.34-36.0% | $-0.25-150.0% | $-0.10 | N/A |
APTN Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $979K-41.1% | $1.7M-41.7% | $2.9M+1092.1% | $239K+74252.5% | $3220.0% | $322-15.3% | $3800.0% | $380 |
| Current Assets | $979K-41.1% | $1.7M-41.7% | $2.9M+6167.2% | $46K+14042.5% | $3220.0% | $322-15.3% | $3800.0% | $380 |
| Cash & Equivalents | $579K-57.2% | $1.4M-43.1% | $2.4M+6865.6% | $34K-70.4% | $115K+385.0% | $24K+6156.8% | $3800.0% | $380 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.9M+56.6% | $1.2M+7.2% | $1.1M-74.5% | $4.3M+33.8% | $3.2M+51.9% | $2.1M+62.1% | $1.3M+34.7% | $978K |
| Current Liabilities | $1.9M+56.6% | $1.2M+7.2% | $1.1M-74.5% | $4.3M+1741.6% | $236K+14.4% | $206K+20.8% | $170K+50.5% | $113K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$881K-285.7% | $474K-72.8% | $1.7M+142.6% | -$4.1M-26.4% | -$3.2M-51.9% | -$2.1M-62.2% | -$1.3M-34.7% | -$978K |
| Retained Earnings | -$7.9M-26.8% | -$6.2M-32.2% | -$4.7M-14.6% | -$4.1M-1648.9% | -$236K-14.4% | -$206K-20.9% | -$171K-50.4% | -$113K |
APTN Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$772K+24.5% | -$1.0M+55.1% | -$2.3M-492.8% | $580K+223.9% | -$468K-129.8% | -$204K-127.2% | -$90K-53.7% | -$58K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $0 | $0-100.0% | $4.6M+780.7% | -$679K-221.2% | $560K+151.6% | $223K+147.3% | $90K+54.2% | $58K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
APTN Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -320.6%-286.0pp | -34.6% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -171.1%-79.6pp | -91.5%-70.3pp | -21.1% | N/A | -343959.9%-89693.5pp | -254266.5%-164942.3pp | -89324.2% | N/A |
| Current Ratio | 0.53-0.9 | 1.40-1.2 | 2.57+2.6 | 0.010.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.00 |
| Debt-to-Equity | -2.11-4.6 | 2.50+1.9 | 0.64+1.7 | -1.06-0.1 | -1.000.0 | -1.000.0 | -1.000.0 | -1.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.29), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
Is Adaptin Bio profitable?
No, Adaptin Bio (APTN) reported a net income of -$5.2M in fiscal year 2025.
What is Adaptin Bio's return on equity (ROE)?
Adaptin Bio (APTN) has a return on equity of -100000000.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Adaptin Bio's operating cash flow?
Adaptin Bio (APTN) generated -$4.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Adaptin Bio's total assets?
Adaptin Bio (APTN) had $619K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Adaptin Bio spend on research and development?
Adaptin Bio (APTN) invested $1.8M in research and development during fiscal year 2025.
What is Adaptin Bio's current ratio?
Adaptin Bio (APTN) had a current ratio of 0.29 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Adaptin Bio's debt-to-equity ratio?
Adaptin Bio (APTN) had a debt-to-equity ratio of 619158.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Adaptin Bio's return on assets (ROA)?
Adaptin Bio (APTN) had a return on assets of -834.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Adaptin Bio's cash runway?
Based on fiscal year 2025 data, Adaptin Bio (APTN) had $459K in cash against an annual operating cash burn of $4.8M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Adaptin Bio's Piotroski F-Score?
Adaptin Bio (APTN) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Adaptin Bio's earnings high quality?
Adaptin Bio (APTN) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Adaptin Bio cover its interest payments?
Adaptin Bio (APTN) has an interest coverage ratio of -74.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Adaptin Bio?
Adaptin Bio (APTN) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.